 |
|
|
|
 |
|
|
| Article 1 to 10 out of 42 concerning QIAGEN N.V.
|
-
QIAGEN acquires Corbett Life Science
(07/02/2008)
Transaction adds proprietary Real-Time PCR detection technologies to QIAGEN's portfolio of molecular testing solutions
QIAGEN N.V. announced that it has acquired Corbett Life Science Pty. Ltd. (Corbett), a privately-held developer, manufacturer, and distributor of life sciences instrumentation headquartered in Sydney, Australia. The transaction is valued at ...
-
Sports Doping Researchers to Tackle Mount Everest
(05/28/2008)
In the run-up to the Olympics scientists use live mice for the first time on the "roof of the world" to develop new tests for gene doping
In the run-up to the Summer Olympics, scientists are taking an innovative approach to develop new molecular testing methods for performance manipulation on the genetic level. A team of researchers from the University of Pennsylvania is attempting to ...
-
QIAGEN and GENEART Partner to Commercialize Synthetic Human Genes
(05/15/2008)
Joint development and collaboration enables enhanced production of every human protein, spurring advances in drug development
QIAGEN and GENEART announced their collaboration to develop, produce and commercialize a new product line for the enhanced production of all 35,000 human proteins. According to the company, QIAgenes is the world's first comprehensive set of plasmids ...
-
QIAGEN and BioHelix Enter Into Licensing Agreement
(05/05/2008)
Helicase-dependent isothermal DNA amplification system provides new assay technology capabilities for QIAGEN's assay automation platforms
QIAGEN and privately held BioHelix have announced that they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to ...
-
QIAGEN Enables Efforts to Eradicate Costly Cattle Disease
(04/23/2008)
Collaboration with Swiss laboratory Microsynth AG pioneers nucleic acid-based primary screening for Bovine Viral Diarrhea
QIAGEN N.V. announced that it has been awarded a contract by the Swiss life science company Microsynth AG to supply the molecular cador BVDV assays for detection of viruses causing Bovine Viral Diarrhea (BVD), one of the most widespread and costly ...
-
U.S. Scientist Receives Otto Warburg Medal Sponsored by QIAGEN
(04/02/2008)
Susan Lindquist Recognized for Contributing to Molecular Understanding of Parkinson's Disease
American scientist Susan Lindquist, Ph.D., was awarded the Otto Warburg Medal in Mosbach, Germany. The medal is considered the most prestigious German award for biochemists and molecular biologists, and is awarded by the German Association of ...
-
QIAGEN to Supply Singapore Ministry of Health with Avian Flu Surveillance Solutions
(01/09/2008)
Exclusive contract is the latest in a series of agreements with international institutions that monitor the spreading of the virus strain
QIAGEN announced that it has been awarded an exclusive contract by the Singapore Ministry of Health to supply sample preparation solutions and molecular tests for the specific detection of Influenza H5N1 viruses - better known as avian flu. For ...
-
QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products
(12/05/2007)
Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions
QIAGEN and Bio*One Capital announced that they have entered into a joint venture to establish Dx Assays Pte Ltd ("Dx Assays"). Dx Assays expects to be one of the first centres in Singapore for assay development in which molecular diagnostics for ...
-
QIAGEN Exchange Offer for Digene Corporation Expired With Significant Over 90% of Shares Tendered
(07/24/2007)
QIAGEN N.V. announced that its offer to exchange cash and stock for all outstanding shares of Digene Corporation expired as scheduled at 11:59 p.m., New York City time, on Friday, July 20, 2007. All conditions of the exchange offer have either been ...
-
QIAGEN and the JCSG Announce Agreement for Commercialization of Sample Technologies for Protein Crystallography
(07/23/2007)
QIAGEN N.V. has entered a strategic agreement with the Joint Center for Structural Genomics (JCSG), one of the 4 PSI Structural Genomics Production Centers, providing protein crystallographers with a new set of proven crystallization screens that ...
Additional information
QIAGEN N.V.
Venlo, Netherlands
Company
|
|
|
|
|
|
Top
